Venous thromboembolism in women taking hormonal contraceptives

References

• Poulter N, Chang C. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case–control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet346, 1575–1582 (1995).
   PubMed Web of Science ®Google Scholar
• Jick H, Jick S, Gurewich V, Myers M, Vasilakis C. Risk of idiopathic cardiovascular death and non-fatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet346, 1589–1593 (1995).
   PubMed Web of Science ®Google Scholar
• Farmer R, Lawrenson R, Thompson C, Kennedy J, Hambleton I. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet349, 83–88 (1997).
   PubMed Web of Science ®Google Scholar
• Wu O, Robertson L, Langhorne P et al. Oral contraceptives, hormonal replacement therapy, thrombophilia and risk of venous thromboembolism: a systematic review. The TREATS Study. Thromb. Haemost.94, 17–25 (2005).
   PubMed Web of Science ®Google Scholar
• Van Vlijmen E, Brouwer J, Veeger N, EskesT, de Graeff P, Van der Meer J. Oral contraceptives and the absolute risk of venous thromboembolism in women with single or multiple thrombophilic defects. Arch. Intern. Med.167, 282–289 (2007).
   PubMed Web of Science ®Google Scholar
• WHO. Cardiovascular disease and steroid hormone contraception. Report of a WHO Scientific group. WHO Technical Report Series 877. WHO, Geneva, Switzerland, 1–89 (1998).
   Google Scholar
• Battaglioli T, Martinelli I. Hormone therapy and thromboembolic disease. Curr. Opin. Hematol.14, 488–493 (2007).
   PubMed Web of Science ®Google Scholar
• Parkin L, Skegg DC, Wilson M, Herbison GP, Paul C. Oral contraceptives and fatal pulmonary embolism. Lancet355, 2133–2134 (2000).
   PubMed Web of Science ®Google Scholar
• Samuelsson E, Hedenmalm K, Persson I. Mortality from venous thromboembolism in young Swedish women and its relation to pregnancy and use of oral contraceptives. An approach to specifying rates. Eur. J. Epidemiol.509–516 (2005).
   PubMed Web of Science ®Google Scholar
• Tans G, Curvers J, Middeldorp S et al. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb. Haemost.84, 15–21 (2000).
   PubMed Web of Science ®Google Scholar
• Gomes MP, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch. Intern. Med.164, 1965–1976 (2004).
   PubMed Web of Science ®Google Scholar
• Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thromboembolism: meta-analysis. Br. Med. J.323, 131–134 (2001).
   PubMed Web of Science ®Google Scholar
• Dinger JC, Heinemann LA, Kühl-Habich D. The safety of drospirenone-containing oral contraceptives: final results from the European Active Surveillance study on oral contraceptives based on 142,475 women-years of observation. Contraception75, 344–354 (2007).
   PubMed Web of Science ®Google Scholar
• Jick S, Kaye JA, Li L, Jick H. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared with users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Contraception76, 4–7 (2007).
   PubMed Web of Science ®Google Scholar
• Bergendal A, Odlind V, Persson I, Kieler H. Limited knowledge on progestagen-only contraception and risk of venous thromboembolism. Acta Obstet. Gynecol. Scand.88, 261–266 (2009).
   PubMed Web of Science ®Google Scholar
• van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJM, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestagen type: results of the MEGA case–control study. Br. Med. J.339, b2921 (2009).
   PubMed Web of Science ®Google Scholar
• Lidegaard O, Lokkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. Br. Med. J.339, b2890 (2009).
   PubMed Web of Science ®Google Scholar
• Blanco-Molina A, Trujillo-Santos J, Tirado R et al. Venous thromboembolism in women using contraceptives. Findings from the RIETE Registry. Thromb. Haemost.101, 478–482 (2009).
   PubMed Web of Science ®Google Scholar
• Blanco-Molina A, Rota L, Di Micco P et al. Venous thromboembolism during pregnancy, postpartum or contraceptive use. Findings from the RIETE Registry. Thromb. Haemost. (2009) (In press).
   Google Scholar
• Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb. Haemost.89, 493–498 (2003).
   PubMed Web of Science ®Google Scholar
• Pomp ER, le Cessie S, Rosendaal FR, Doggen CJ. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br. J. Haematol.139, 289–296 (2007).
   PubMed Web of Science ®Google Scholar
• ACOG Practice Bulletin No. 73. Use of hormonal contraception in women with coexisting medical conditions. Clinical management guidelines for obstetrician–gynecologists. Obstet. Gynecol.107, 1453–1472 (2006).
   PubMedGoogle Scholar
• Geerts WH, Bergqvist D, Pineo GF et al. Prevention of venous thromboembolism. American College of Chest Physicians Evidence-based Clinical Practice Guidelines (8th Edition). Chest133, 381s–453s (2008).
   PubMed Web of Science ®Google Scholar
• Bloemenkamp KWM, Rosendaal FR, Helmersorst FM, Vandenbrouke JP. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch. Intern. Med.160, 49–52 (2000).
   PubMedGoogle Scholar
• Scarabin P-Y, Oger E, Plu-Bureau G; ESTHER study group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet362, 428–432 (2003).
   PubMed Web of Science ®Google Scholar
• Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet344, 1454–1457 (1994).
   Google Scholar
• Roldán V, Lecumberri R, Muñoz-Torrero JF et al. Thrombophilia testing in patients with venous thromboembolism. Findings from the RIETE Registry. Thromb. Res.124, 174–177 (2009).
   PubMed Web of Science ®Google Scholar
• Wu O, Robertson L, Twaddle S et al. Screening for thrombophilia in high-risk situations: a meta-analysis and cost–effectiveness analysis. Brit. J. Haematol.131, 80–90 (2005).
   PubMed Web of Science ®Google Scholar
• Smith KJ, Monsef BS, Ragni MV. Should female relatives of factor V Leiden carriers be screened prior to oral contraceptive use? Thromb. Haemost.100, 447–452 (2008).
   PubMed Web of Science ®Google Scholar
• Savelli S, Kerlin B, Springer M, Monda K, Thornton J, Blanchong C. Recommendations for screening for thrombophilic tendencies in teenage females prior to contraceptive initiation. J. Pediatr. Adolesc. Gynecol.19, 313–316 (2006).
   PubMedGoogle Scholar
• Eichinger S. Consequences of thrombophilia screening for life quality in women before prescription of oral contraceptives and family members of VTE patients. Hämostaseologie1, 110–111 (2009).
   Google Scholar